Arkolith/Insider Trading/SNSE/Form 4

Peyer James

Director, 10% OwnerSensei Biotherapeutics, Inc. (SNSE) · full profile →Form 4 · filed Aug 2, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 31, 2023Disposed to issuer(D)1.6M$1.26$2.0M3.7M

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000897069-23-001052) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML